Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

SAB Biotherapeutics, Inc. (SABS)

1.6901
+0.0701
+(4.33%)
At close: May 7 at 4:00:00 PM EDT
Loading Chart for SABS
  • Previous Close 1.6200
  • Open 1.6900
  • Bid --
  • Ask --
  • Day's Range 1.6900 - 1.7912
  • 52 Week Range 1.0000 - 5.0100
  • Volume 57,751
  • Avg. Volume 56,206
  • Market Cap (intraday) 15.699M
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) --
  • EPS (TTM) -3.6800
  • Earnings Date May 19, 2025 - May 23, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.60

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

www.sabbiotherapeutics.com

63

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SABS

View More

Performance Overview: SABS

Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SABS
55.45%
S&P 500 (^GSPC)
4.26%

1-Year Return

SABS
58.68%
S&P 500 (^GSPC)
8.55%

3-Year Return

SABS
92.72%
S&P 500 (^GSPC)
36.57%

5-Year Return

SABS
98.35%
S&P 500 (^GSPC)
95.45%

Compare To: SABS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SABS

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    15.70M

  • Enterprise Value

    -392.68k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.60

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -41.86%

  • Return on Equity (ttm)

    -81.92%

  • Revenue (ttm)

    1.32M

  • Net Income Avi to Common (ttm)

    -34.11M

  • Diluted EPS (ttm)

    -3.6800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.76M

  • Total Debt/Equity (mrq)

    17.98%

  • Levered Free Cash Flow (ttm)

    -22.1M

Research Analysis: SABS

View More

Company Insights: SABS

Research Reports: SABS

View More

People Also Watch